Lyell Immunopharma

Lyell Immunopharma is a South San Francisco-based clinical-stage cell therapy company developing next-generation CAR T-cell product candidates for hematologic malignancies and solid tumors. Its lead asset, rondecabtagene autoleucel (ronde-cel), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in the pivotal PiNACLE trial in third-line-or-later large B-cell lymphoma and in the Phase 3 PiNACLE-H2H head-to-head study in the second-line setting, with updated data across more than 80 patients reported ahead of ASH 2026. A second programme, LYL273, is a GCC-targeted CAR T enhanced with CD19 CAR expression and controlled cytokine release in Phase 1/2 for refractory metastatic colorectal cancer. The company's LyFE Manufacturing Center is designed to support registrational and commercial supply, and its platform work spans c-Jun overexpression, NR4A3 knockout, Epi-R and CD62L-positive enrichment to resist T-cell exhaustion. Lyell was incorporated in 2018, listed on Nasdaq in June 2021, and is led by President and Chief Executive Officer Lynn Seely, with founder Richard Klausner as Executive Chairman.